The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (65.97) USD. With the latest stock price at 46.84 USD, the upside of Nektar Therapeutics based on DCF is -240.9%.
Based on the latest price of 46.84 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 240.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 8.5% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (171.43) - (41.43) | (65.97) |
| Upside | -466.0% - -188.5% | -240.9% |